Browsing by Author "Ibrahim, M.A."

Now showing 1 - 1 of 1
  • Item
    Compaction Characteristics of a Micro-structured Filler-binder “Microcrystarcellactose B3” for direct compression tableting
    (Faculty of Pharmaceutical Sciences, University of Jos, 2018) Shittu, A.O.; Oyi, A.R.; Isah, A.B.; Ibrahim, M.A.
    A research was conducted to develop and evaluate a highly compressible micro-structured filler- binder for direct compression tableting. Tapioca starch (TS) was annealed, hydrolyzed and coprocessed with α-lactose monohydrate (α-LMH) and microcrystalline cellulose (MCC) to yield a novel microcrystarcellactose (MSCL B3). The powder suspensions were prepared at a concentration of 40 %w/w in five separate conical flasks. The TS granules were annealed for 1 h and subsequently hydrolyzed with α-amylase at 58o and pH 7 for 1, 2, 3, 4, and 5 h respectively. The reaction was terminated and neutralized with 0.1 N HCL and 0.1 N NaOH respectively. The enzyme hydrolyzed starch (EHS) at 3 h, sieved fraction >75-250 μm was coprocessed with α-LMH and MCC and compressed with load ranging from 2.5 to 12.5 KN. MSCL B3 (component ratio of EHS, α-LMH, and MCC ‘35: 35:30’) possessed improved functionality over direct physical mixture of the excipients. The Py (yield values) are: Cellactose (24.2 MNm-2) > MCC (25 MNm-2) > MSCL B3 (50.0 MNm-2) > Starlac (143 MNm-2). The degree of plastic deformation occurring “Pk” are in the following order: MSCL B3 (17.0 MNm-2) = Cellactose ® (17.0 MNm-2) > MCC (18.6 MNm-2) > Starlac® (19.1 MNm-2). MSCL B3 is as good as Cellactose® and more superior in functionality than Starlac® and MCC. The dilution potential for MSCL B3 in PCM and AA tablets were: 45% and 50 % respectively. MSCL B3 can be used to formulate softer tablet of both poorly compressible API and moisture sensitive API